Unknown

Dataset Information

0

Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.


ABSTRACT: Psoriasis is a chronic, inflammatory, immune-mediated skin condition that affects 3 to 4% of the adult US population, characterized by well-demarcated, erythematous plaques with silver scale. Psoriasis is associated with many comorbidities including cardiometabolic disease and can have a negative impact on quality of life. The current armamentarium of psoriasis treatment includes topical therapies, phototherapy, oral immunosuppressive therapies, and biologic agents. Over the past 2 decades, there has been rapid development of novel biologic therapies for the treatment of moderate-to-severe plaque psoriasis. This article will review the role of IL-12, IL-23, and IL-17 in the pathogenesis of psoriasis and the monoclonal antibodies (ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, and risankizumab) that target these cytokines in the treatment of this disease.

SUBMITTER: Jeon C 

PROVIDER: S-EPMC5647990 | BioStudies | 2017-01-01T00:00:00Z

SECONDARY ACCESSION(S): NCT01722331

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6693782 | BioStudies
2020-01-01 | S-EPMC6994587 | BioStudies
2019-01-01 | S-EPMC6754904 | BioStudies
2016-01-01 | S-EPMC4799039 | BioStudies
2019-01-01 | S-EPMC6691125 | BioStudies
2019-01-01 | S-EPMC6771721 | BioStudies
2017-01-01 | S-EPMC5600287 | BioStudies
2020-01-01 | S-EPMC7688845 | BioStudies
1000-01-01 | S-EPMC5698206 | BioStudies
2019-01-01 | S-EPMC6587780 | BioStudies